tradingkey.logo

Century Therapeutics Inc

IPSC
0.560USD
-0.013-2.30%
收盤 11/05, 16:00美東報價延遲15分鐘
48.32M總市值
虧損本益比TTM

Century Therapeutics Inc

0.560
-0.013-2.30%

關於 Century Therapeutics Inc 公司

Century Therapeutics, Inc. 是一家生物技術公司。該公司專注於開發轉化性同種異體細胞療法,以創造用於治療具有未滿足醫療需求的實體瘤和血液系統惡性腫瘤的產品。該公司已經創建了同種異體細胞治療平臺,其中包括誘導多能幹細胞 (iPSC)、從 iPSC 或 iPSC 衍生細胞產生免疫效應細胞的分化技術、成簇的規律間隔的短迴文重複序列,以整合多個轉基因並去除靶基因。該公司的候選產品包括 CNTY-101、CNTY-102、CNTY-107、CNTY-104 和 CNTY-106。其 CNTY-101 專注於靶向 CD19 治療複發性、難治性 B 細胞淋巴瘤。CNTY-102 靶向 CD19 + CD22 治療複發性、難治性 B 細胞淋巴瘤和其他 B 細胞惡性腫瘤。 CNTY-107用於治療表達Nectin-4的實體瘤。CNTY-106是針對多發性骨髓瘤的多特異性合作方案。

Century Therapeutics Inc簡介

公司代碼IPSC
公司名稱Century Therapeutics Inc
上市日期Jun 17, 2021
CEODr. Brent Pfeiffenberger, Pharm.D.
員工數量140
證券類型Ordinary Share
年結日Jun 17
公司地址25 N 38Th Street, 11Th Floor
城市PHILADELPHIA
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編19104
電話12159814000
網址https://www.centurytx.com/
公司代碼IPSC
上市日期Jun 17, 2021
CEODr. Brent Pfeiffenberger, Pharm.D.

Century Therapeutics Inc公司高管

名稱
名稱/職務
職務
持股
持股變動
Dr. Brent Pfeiffenberger, Pharm.D.
Dr. Brent Pfeiffenberger, Pharm.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
2.04M
-0.02%
Dr. Chad Cowan, Ph.D.
Dr. Chad Cowan, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
992.85K
+331.10%
Mr. Douglas Carr, CPA
Mr. Douglas Carr, CPA
Interim Chief Financial Officer
Interim Chief Financial Officer
423.31K
-0.06%
Dr. Gregory (Greg) Russotti, Ph.D.
Dr. Gregory (Greg) Russotti, Ph.D.
Chief Technology and Manufacturing Officer
Chief Technology and Manufacturing Officer
379.67K
-0.14%
Dr. Kimberly Lynn Blackwell, M.D.
Dr. Kimberly Lynn Blackwell, M.D.
Independent Director
Independent Director
--
--
Ms. Daphne E. Quimi, CPA
Ms. Daphne E. Quimi, CPA
Independent Director
Independent Director
--
--
Mr. Timothy P. (Tim) Walbert
Mr. Timothy P. (Tim) Walbert
Independent Director
Independent Director
--
--
Dr. Carlo Rizzuto, Ph.D.
Dr. Carlo Rizzuto, Ph.D.
Independent Director
Independent Director
--
--
Dr. Alessandro Riva, M.D.
Dr. Alessandro Riva, M.D.
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Dr. Brent Pfeiffenberger, Pharm.D.
Dr. Brent Pfeiffenberger, Pharm.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
2.04M
-0.02%
Dr. Chad Cowan, Ph.D.
Dr. Chad Cowan, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
992.85K
+331.10%
Mr. Douglas Carr, CPA
Mr. Douglas Carr, CPA
Interim Chief Financial Officer
Interim Chief Financial Officer
423.31K
-0.06%
Dr. Gregory (Greg) Russotti, Ph.D.
Dr. Gregory (Greg) Russotti, Ph.D.
Chief Technology and Manufacturing Officer
Chief Technology and Manufacturing Officer
379.67K
-0.14%
Dr. Kimberly Lynn Blackwell, M.D.
Dr. Kimberly Lynn Blackwell, M.D.
Independent Director
Independent Director
--
--
Ms. Daphne E. Quimi, CPA
Ms. Daphne E. Quimi, CPA
Independent Director
Independent Director
--
--

收入明細

暫無數據
暫無數據
業務
地區
暫無數據

股東統計

更新時間: 9月23日 週二
更新時間: 9月23日 週二
持股股東
股東類型
持股股東
持股股東
佔比
Bayer AG
14.67%
Versant Ventures
14.08%
Fujifilm Holdings Corp
8.05%
Bain Capital Life Sciences Investors, LLC
6.26%
The Vanguard Group, Inc.
2.44%
其他
54.49%
持股股東
持股股東
佔比
Bayer AG
14.67%
Versant Ventures
14.08%
Fujifilm Holdings Corp
8.05%
Bain Capital Life Sciences Investors, LLC
6.26%
The Vanguard Group, Inc.
2.44%
其他
54.49%
股東類型
持股股東
佔比
Corporation
22.72%
Investment Advisor
14.84%
Venture Capital
14.08%
Hedge Fund
9.77%
Individual Investor
5.99%
Investment Advisor/Hedge Fund
2.22%
Research Firm
0.81%
Private Equity
0.03%
Family Office
0.03%
其他
29.51%

機構持股

更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
172
36.07M
41.76%
-14.03M
2025Q2
185
65.43M
75.94%
-12.74M
2025Q1
190
67.80M
85.48%
-12.38M
2024Q4
199
74.05M
87.09%
-5.74M
2024Q3
197
77.29M
91.61%
-2.73M
2024Q2
195
76.53M
90.84%
+3.21M
2024Q1
192
59.55M
90.31%
-4.03K
2023Q4
185
53.19M
83.25%
-1.66M
2023Q3
177
52.18M
87.54%
-4.25M
2023Q2
185
53.42M
89.72%
-5.97M
查看更多

股東持股明細

名稱
持股數
佔比
持股變動
變動比例
公告日期
Bayer AG
12.68M
14.67%
--
--
Apr 15, 2025
Versant Ventures
12.17M
14.08%
--
--
Apr 15, 2025
Fujifilm Holdings Corp
6.96M
8.05%
--
--
Apr 15, 2025
Bain Capital Life Sciences Investors, LLC
5.41M
6.26%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
2.11M
2.44%
-267.41K
-11.25%
Jun 30, 2025
Pfeiffenberger (Brent)
2.04M
2.36%
-488.00
-0.02%
Sep 08, 2025
Renaissance Technologies LLC
2.02M
2.34%
+837.18K
+70.63%
Jun 30, 2025
Dafna Capital Management, LLC
1.70M
1.97%
--
--
Jun 30, 2025
Casdin Capital, LLC
1.23M
1.42%
-1.98M
-61.77%
Jun 30, 2025
Syncona Portfolio Ltd
1.21M
1.4%
--
--
Jun 30, 2025
查看更多

持股ETF

更新時間: 11月2日 週日
更新時間: 11月2日 週日
機構名稱
佔比
ProShares Hedge Replication ETF
0%
ProShares UltraPro Russell2000
0%
Schwab U.S. Small-Cap ETF
0%
Schwab U.S. Broad Market ETF
0%
Proshares Ultra Russell 2000
0%
iShares Micro-Cap ETF
0%
iShares Russell 3000 ETF
0%
Global X Russell 2000 Covered Call ETF
0%
iShares Russell 2000 Value ETF
0%
Dimensional US Core Equity 1 ETF
0%
查看更多
ProShares Hedge Replication ETF
佔比0%
ProShares UltraPro Russell2000
佔比0%
Schwab U.S. Small-Cap ETF
佔比0%
Schwab U.S. Broad Market ETF
佔比0%
Proshares Ultra Russell 2000
佔比0%
iShares Micro-Cap ETF
佔比0%
iShares Russell 3000 ETF
佔比0%
Global X Russell 2000 Covered Call ETF
佔比0%
iShares Russell 2000 Value ETF
佔比0%
Dimensional US Core Equity 1 ETF
佔比0%

分紅派息

近5年累計派現 0.00 美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據

拆合股

公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
KeyAI